The Lancet Haematology in conversation with artwork

Fredrik Schjesvold on OCEAN phase 3

The Lancet Haematology in conversation with

English - January 31, 2022 23:00 - 12 minutes - 8.55 MB
Life Sciences Science Education blood haemophilia haematology leukaemia Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Jacob D Soumerai and Andrew D Zelenetz on the BOVen regimen for previously untreated patients with chronic lymphocytic leukaemia

Next Episode: Nicholas Crombie and Gavin Perkins on resuscitation with blood products compared with saline

Dr Fredrik Schjesvold discusses the results of the OCEAN phase 3 trial testing melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide.

Read the full article:
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN)

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv